Name (Synonyms) | Correlation | |
---|---|---|
drug2126 | Placebo (carrier control) Wiki | 1.00 |
drug1376 | Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (MSC), with intravenous (IV) administration in hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19.
Description: Number of subjects with a DLT event during or within 24 hours after ULSC infusion [Dose Limiting Toxicities are treatment-emergent suspected adverse reactions graded as severe, such as severe infusion-related hypersensitivity toxicities of grade ≥3, and any treatment-emergent serious adverse event (SAE) will be investigated to determine if DLT.]
Measure: Incidence of Dose Limiting Toxicity (DLT) Time: 24 hoursDescription: Number of subjects with a DLT event, suspected adverse reaction, or any serious adverse event (SAE) within 1 week of each ULSC infusion
Measure: Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE) Time: 1 weekDescription: Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study up to 1-month follow-up
Measure: Treatment-emergent adverse events (AE) and serious adverse events (SAE) Time: 1 monthDescription: Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study and up to the 12-month follow-up
Measure: Treatment-emergent adverse events (AE) and serious adverse events (SAE) Time: 12 monthsDescription: Times to transitions between levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS
Measure: Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS Time: 1 monthDescription: Changes in SpO2/FiO2 ratio or pAO2/FiO2 ratio compared to baseline, measured daily at a minimum; oxygenation index daily when on ventilator
Measure: Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio Time: 1 monthDescription: Number of ventilator-free days (VFD) in period of 1 month from study treatment
Measure: Number of ventilator-free days (VFD) Time: 1 monthDescription: Changes in CBC with differential from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in Complete Blood Count (CBC) with differential from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in blood glucose (mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of blood glucose (mg/dL) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of sodium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of sodium (mEq/L) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of potassium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of potassium (mEq/L) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of alanine transaminase (ALT; U/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of alanine transaminase (ALT; U/L) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Change in Urinalysis (UA) at baseline and 1 month after study treatment to assess for presence and qualitative proteinuria
Measure: Change in Urinalysis (UA) from baseline Time: 1 month